Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Core Insights - Genenta Science has provided an update on its TEM-GBM study for newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT gene promoter, reporting that 25 patients have been treated with Temferon as of November 21, 2025 [1][2] Group 1: Clinical Study Results - Key survival metrics for TEM-GBM patients show that 44% of patients have reached 18-month survival, an increase from 38% reported in April 2025 [7] - The two-year survival rate remains at 29%, and the median overall survival is consistent at 17 months, compared to historical cohorts of uMGMT patients treated with standard care, which typically show a two-year survival rate of approximately 14% and median overall survival of 13-15 months [7] - The study includes a patient who has reached three years of survival following Temferon administration, marking a significant milestone in the study [7] Group 2: Mechanism and Observations - The GBM study provides early observations on Temferon's behavior within the tumor microenvironment, indicating that bone-marrow-derived myeloid cells can deliver immunotherapeutic payloads at the tumor site, aligning with the platform's intended design [3] - These preliminary findings are exploratory and will inform the broader development of Temferon, including potential combination approaches and the evolution of the underlying cell-based delivery technology [3] Group 3: Financial Position - Following a registered direct offering on October 27, the company reported approximately $30 million in cash and short-term investments as of November 1, 2025 [4] Group 4: Company Overview - Genenta Science is a clinical-stage immuno-oncology company developing a proprietary hematopoietic stem cell therapy for various solid tumor cancers, with Temferon as its first-in-class product candidate [5] - The company has completed a Phase 1 trial for newly diagnosed GBM patients with an unmethylated MGMT gene promoter, suggesting potential reprogramming of the tumor microenvironment and induction of T cell responses [5] - Genenta has also initiated a Phase 1/2a study for metastatic Renal Cell Carcinoma, which will include combinations with immune checkpoint inhibitors [5]